The V7 ultrasound system offers a broad range of clinical applications to improve patient as well as user experience.
The US Food and Drug Administration recently granted 510(k) clearance for its commercial use.
V7 has been developed to overcome difficult clinical cases with accuracy and precision in busy ultrasound settings.
It offers imaging specialists in hospital departments a multi-faceted diagnostic experience.
The new ultrasound system is developed based on Crystal Architecture to provide improved image clarity and penetration.
It combines beamforming (CrystalBeam), sophisticated image processing (CrystalLive) and advanced S-Vue Single Crystal Transducers to produce images that are clear, uniform and high resolution.
Boston Imaging head and vice-president David Legg said: “There is a continued demand on imaging professionals to deliver high-quality results in an efficient amount of time, without compromising patient care.
“We’re proud to help address this by supplying one more solution that helps make clinical assessments effortless and treatment precise.”
The V7 ultrasound system is equipped with various Intelligent Assist features that allow it to be used in general imaging as well as women’s health ultrasound cases.
It has a 2D Follicle, an automated measurement tool that identifies and measures follicle size based on a 2D image and provides information regarding the status of follicles during gynaecology examinations, as well as an AutoIMT screening tool for evaluating a patient’s potential risk of cardiovascular disease.
It also includes an S-Shearwave Imaging tool, which offers non-invasive assessment and documentation of tissue stiffness for clinical applications.
Additionally, V7 incorporates UterineAssist artificial intelligence technology that measures the uterus’ size and shape automatically to help detect any uterine-related abnormalities.
Furthermore, the system has an E-Cervix elastography technology that provides an efficient semi-quantitative evaluation of stiffness in the cervical canal.